WonderLab

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

WonderLab - overview

Established

2017

Location

Beijing, -, China

Primary Industry

Healthcare Specialists

About

Based in Beijing, China and founded in 2017, Adai Technology (Beijing) Co. , Ltd. , trading as WonderLab, is a digital medical service provider that focuses on the digital therapy of mental diseases. It has cooperated with three domestic mental illness medical institutions, including The Second Xiangya Hospital of Central South University, The Sixth Hospital of Peking University, and The Shanghai Mental Health Center.


And its team members graduated from domestic and overseas universities, such as Peking University, Tsinghua University, New York University, and Columbia University. Moreover, its product, indications for cognitive impairment, received digital therapy registration certification. In March 2026, WonderLab closed Series B+ funding from Marathon Venture Partners. The company has a self-developed platform for digital therapy of mental illness.


The platform helps treat mental illnesses and improve mental health through artificial intelligence technology, and physiological data. Besides, the platform provides digital therapy for mental illnesses of depression, addiction, sleep problems, Alzheimer's, cognitive impairment, anxiety, and autism. It also developed applications for patients and administrators. And the platform has accumulated more than tens of thousands of patient data for electrophysiology, behavior, and medical diagnosis, which enables improved accuracy of the model.


The company generates revenue through providing a self-developed platform for digital therapy of mental illness. The Series B+ funding raised in March 2026 will primarily be used for product research and development.


Current Investors

Taiyou Fund, Long Hill Capital, HCH Capital

Primary Industry

Healthcare Specialists

Sub Industries

Healthcare IT, Mental Health Services, Medical Software

Website

www.wangli-tech.com

Verticals

Artificial Intelligence, HealthTech, Mobile Apps

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.